Expert views and opinion
International experts discuss hot topics in the modern management of patients with dyslipidaemia.
- Cholesterol metabolism
- The role of PCSK9 in lipid metabolism
- Modern diagnosis and management of familial hypercholesterolaemia around the world
- Recent trials
- Key messages from international congresses
Henry Ginsberg What’s new on the horizon for lipoprotein(a) therapies?
Steve Nicholls Should ACS patients start a PCSK9 inhibitor in hospital?
Steve Nicholls APOLLO trial with SLN360
Tycho Tromp What can we learn from the Homozygous Familial Hypercholesterolaemia International Clinical Collaboration registry?
Kiran Musunuru What does the future hold for CRISPR base editing of PCSK9?
Frederick J. Raal ESC 2021 Inclisiran in polyvascular disease
Steve Nicholls Huygens: Does PCSK9 inhibition impact the vulnerable plaque?
John Chapman LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Chris Packard Why should clinical practice move to an intensive LDL-C lowering approach?
Chris Packard How do clinicians translate intensive LDL-C lowering to their practice?
Are very low lipoprotein(a) levels safe? Insights from the Copenhagen General Population Study
Which lipid markers best identify residual risk in statin-treated patients?
Chris Packard Very low lipoprotein(a) and very low LDL cholesterol – are they safe?
Frederick J. Raal Combination therapy in familial hypercholesterolaemia: what can we gain from novel agents?
Steve Nicholls Triglyceride lowering and residual risk: what can we learn from the trials?
VIDEO: GPs in FH care
VIDEO: New FH guidance for Australasia
VIDEO: The SAMSON Study
VIDEO: Evinacumab in refractory hypercholesterolaemia
Steve Nicholls VIDEO: Prof Steve Nicholls discusses STRENGTH
Steve Nicholls VIDEO: Prof Steve Nicholls fish oils and AF
VIDEO: Do we treat high LDL-C in the ‘healthy’ elderly?
Raul Santos Professor Santos discusses HAUSER-RCT
VIDEO: Prof PG Steg Targeting PCSK9 inhibition
VIDEO: Prof Greg Schwartz Candidates for PCSK9 inhibition
VIDEO: Prof Eric Bruckert EAS FHSC Registry
VIDEO: Prof Eric Bruckert LDL goals in FH
VIDEO: Prof Raul Santos discusses the EAS FHSC Global Registry
VIDEO: Professor Gregory Schwartz on the USA versus European lipid guidelines
VIDEO: Dr Robert Giugliano discusses the lipid guidelines
VIDEO: Key messages from the 2019 ESC EAS dyslipidaemia guidelines
VIDEO: ORION 11
VIDEO: EVOPACS evolocumab in the acute ACS setting
VIDEO: 2019 ESC EAS Dyslipidaemia Guidelines
VIDEO: Very low LDL C levels in ODYSSEY OUTCOMES
VIDEO: Real world use of evolocumab in FH
Steve Nicholls VIDEO: Prof Stephen Nicholls Targeting PCSK9 inhibitors to the right patient
Steve Nicholls VIDEO: Prof Stephen Nicholls Effect of alirocumab on MI types
VIDEO: Novel PCSK9 therapeutics
VIDEO: BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids
VIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points
VIDEO: Coronary artery calcium for stratifying risk in familial hypercholesterolaemia
VIDEO: PCSK9 Forum Inhibitors and Health Economics
Gregory G. Schwartz VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study
Gregory G. Schwartz VIDEO: New insights from ODYSSEY OUTCOMES
John Chapman VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)
VIDEO: Why we need to avoid recurrent events: Plaque biology considerations
REDUCE-IT- does the formulation matter?
REDUCE-IT take home messages
More guideline controversy
Are we ready to test the lipoprotein(a) hypothesis
AHA 2018 ODYSSEY Alternative Extension Trial
VIDEO: AHA 18 ODYSSEY OUTCOMES Take Home Messages from Total Events Analysis
AHA 2018 ODYSSEY OUTCOMES Total Events Analysis
VIDEO: AHA 2018 US Cholesterol Guidelines
Dr Brian Ference sets the record straight on questions about benefit in FOURIER
FOURIER update: new impetus for guideline groups to reconsider LDL targets
Is lowering lipoprotein(a) beneficial when LDL-C is very low?
VIDEO: How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes
VIDEO: What’s in the PCSK9 pipeline?
VIDEO: EAS Congress: Lowering lipoprotein(a) for clinical benefit: How much?
EAS Consensus Panel: Statins do not impair cognitive function
EAS Congress: FOURIER analysis shows benefit of PCSK9 inhibition in patients with elevated lipoprotein(a)
The Word from ACC 2018: ODYSSEY Outcomes
Highlights from ACC.2018: Poster presentations
Kausik Ray VIDEO: Will the trial evidence now overcome barriers to the use of PCSK9 inhibition?
Steve Nicholls Will FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?
Ulf Landmesser VIDEO: Do FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?
Steve Nicholls Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?
Steve Nicholls Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): Would you have expected a greater magnitude of benefit for the primary outcome in ODYSSEY Outcomes?
Raul Santos Professor Raul Santos (University of São Paulo, Brazil): Why was the mortality benefit in ODYSSEY Outcomes only evident after 1 year of follow-up?
Raul Santos Professor Raul Santos (University of São Paulo, Brazil): What are the key take home messages from ODYSSEY Outcomes?
Raul Santos Will ODYSSEY Outcomes change the management of ACS patients?
Lluís Masana What is the take home message from ODYSSEY Outcomes regarding the role of LDL cholesterol in CVD prevention?
Francois Mach How do you explain the different mortality results in ODYSSEY Outcomes versus FOURIER?
Steve Nicholls Does ODYSSEY Outcomes align with FOURIER and the SPIRE cardiovascular outcomes studies?
ODYSSEY Outcomes and FOURIER in context
Inclisiran marches on: ORION-4 cardiovascular outcomes study launches
Prof John Chapman discusses safety data from the ODYSSEY Outcomes study
Prof Henry Ginsberg discusses the ODYSSEY Outcomes topline data
Prof Greg Schwartz Clinical implications of ODYSSEY Outcomes
Prof Greg Schwartz Key results of ODYSSEY Outcomes
Prof Greg Schwartz Rationale and design of ODYSSEY Outcomes
WOSCOPS analysis: Take home messages for clinicians
Implications from the WOSCOPS analysis
Ulf Landmesser ESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors
Frederick J. Raal Treatment with evolocumab avoids the use of lipoprotein apheresis in high risk patients
Bertrand Cariou ORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses
TAUSSIG: Evolocumab shows benefit in children with homozygous familial hypercholesterolaemia
Anthony Wierzbicki Will CANTOS and REVEAL change how we view the clinical use of PCSK9 inhibitors?
John Chapman VIDEO: Implications of very low LDL cholesterol levels
How does statin intolerance impact on clinical outcome?
How to diagnose statin intolerance?
Peter Lansberg Dr Peter Lansberg: What does FOURIER mean for FH patients?
John Chapman The Word from ACC 2017 – Implications for Practice
John Chapman The Word from ACC 2017 – Key Results
VIDEO: Access to PCSK9 inhibitor treatment: NLA survey provides important pointers
Henry Ginsberg John Chapman FOURIER in the Hot Seat: What are the Implications for practice and access?
Brian Ference Dr Brian Ference sets the record straight on questions about benefit in FOURIER
Evan Stein Events are the driver in PCSK9 cardiovascular outcomes trials
Evan Stein Prof Evan Stein: What are the key messages from FOURIER?
Ulf Landmesser Prof Ulf Landmesser: How can we ensure the best value from PCSK9 inhibitor therapy?
Steve Nicholls Prof Steve Nicholls: How can FOURIER improve our clinical practice?
Ulf Landmesser Prof Ulf Landmesser: How will FOURIER impact practice?
Steve Nicholls Prof Steve Nicholls: Is there a link between the benefit of evolocumab observed in GLAGOV & FOURIER?
Steve Nicholls Prof Steve Nicholls: Is FOURIER a game changer?
Prof Robert Rosenson: REGARDS study adds to EBBINGHAUS reassures on lack of effect on neurocognition at low LDL-C
Raul Santos VIDEO: Prof Raul Santos: How can PCSK9 monoclonal antibody therapy be cost effective?
Kausik Ray Prof Kausik Ray: How will FOURIER impact FH care?
Francois Mach Prof Francois Mach: How will FOURIER impact guidelines
Francois Mach Prof Francois Mach discusses EBBINGHAUS
Raul Santos Prof Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition
Kausik Ray Prof Kausik Ray: Inclisiran, new kid on the block, looks good in ORION
Kausik Ray Prof Kausik Ray: Analyses FOURIER, SPIRE-2 and ODYSSEY outcomes
Henry Ginsberg Prof Henry Ginsberg: Data needed on the diabetes subgroup in FOURIER
Raul Santos Prof Raul Santos: SPIRE trials with bococizumab
Philip Barter Prof Philip Barter: How do we translate the FOURIER data to clinical practice?
John Chapman Prof John Chapman: FOURIER – Why was there no significant effect on CV mortality?
John Chapman Prof John Chapman: FOURIER endpoint data
Philip Barter PCSK9 Forum Editor Professor Philip Barter discusses FOURIER
Philip Barter Take home message on FOURIER
Henry Ginsberg PCSK9 Forum Editor Professor Henry Ginsberg discusses FOURIER
Anthony Wierzbicki Countdown to FOURIER: What are the implications for patients?
Philip Barter Could PCSK9 inhibitors be used in FH children?
Anthony Wierzbicki Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
John Chapman Looking back at 2016: What made the news?
PCSK9 inhibitors: cardiovascular benefit vs. diabetes risk
Anthony Wierzbicki Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016
Anthony Wierzbicki Heart UK statement on homozygous familial hypercholesterolaemia places PCSK9 inhibitors as second‑line treatment
Raul Santos SAFEHEART: Consider more than coronary complications in FH
Henry Ginsberg PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
Peter Lansberg ODYSSEY ESCAPE: a view from PCSK9 Forum
Peter Lansberg News: International Atherosclerosis Society consensus statement on severe familial hypercholesterolaemia
Frederick J. Raal Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia?
Frederick J. Raal Peter Lansberg Low LDL-C, PCSK9 and dementia risk?
Frederick J. Raal TAUSSIG: Does adding evolocumab reduce cardiovascular events in homozygous FH?
Peter Lansberg Changing the message on LDL cholesterol: Lifetime exposure is key
Steve Nicholls ESC Congress 2015 buzz: Novel LDL lowering treatments
Peter Lansberg Hot Topic siRNA and PCSK9
Eric Bruckert ODYSSEY 78 week HeFH data: Clinical perspectives
Steve Nicholls PCSK9 therapeutics – the next story?
What’s next in the PCSK9 field: small interference RNA therapeutics
Frederick J. Raal Start treatment early: Maximise benefit
Peter Lansberg Dutch experience – Improving detection and care
Steve Nicholls How will PCSK9 inhibitors be used in practice?
Philip Barter New cholesterol lowering drugs in news
Joost Besseling Consider FH in young heart attack patients
Sam Gidding Making premature CHD history
Sam Gidding How to identify children with FH
Albert Wiegman Safety of lowering LDL-C
Raul Santos EAS Consensus Panel on Paediatric FH
Frederick J. Raal ISA 2015: Evolocumab in TAUSSIG homozygous FH cohort
Henry Ginsberg John Chapman New era in cholesterol-lowering? PCSK9 inhibitors soon available?
Albert Wiegman Sam Gidding ISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia
Pablo Corral FH in Argentina: Why the European Atherosclerosis Society FH Studies Collaboration (EAS-FHSC) is key
Erik Stroes European Atherosclerosis Society Consensus Panel on statin-associated muscle symptoms: Professor Erik Stroes, Academic Medical Center, the Netherlands
Henry Ginsberg PCSK9 and Lp(a), a novel approach to a re-emergent cardiovascular risk factor
Lluís Masana Weighing the cost versus benefit of PCSK9-targeted therapy
Lluís Masana High cholesterol: an unmet need
Henry Ginsberg Looking ahead with PCSK9 Education & Research Forum
Henry Ginsberg What are the patient priorities for PCSK9 inhibitors?
Steve Nicholls Does PCSK9 inhibition impact atherosclerosis?
Anne Tybjaerg-Hansen Loss of function mutations in PCSK9: the trigger for therapeutic development
Bertrand Cariou Does PCSK9 have effects beyond the liver and if so, what is the evidence?
Katherine Wilemon Familial hypercholesterolaemia: putting the patient first
Frederick J. Raal Overlap between HoFH and severe FH and implications for evolocumab
Frederick J. Raal Implications from TESLA for FH management
Gerald Watts Implications from TESLA and early TAUSSIG studies with evolocumab
Dirk Blom The role of PCSK9 inhibitors in FH
Evan Stein What are the gaps in knowledge about the PCSK9 inhibitors
Frederick J. Raal Do the PCSK9 monoclonal antibodies have neurocognitive effects
Frederick J. Raal Will the PCSK9 monoclonal antibodies replace other lipid lowering treatment used with statins
Henry Ginsberg New ACC/AHA guidelines for cholesterol management: View from the Editors
Henry Ginsberg LDL-C: how low should clinicians aim for?
Evan Stein Lowering LDL-C: How low and for how long?
Albert Wiegman Why is it critical to target children with FH?
Gerald Watts Professor Gerald Watts discusses the 10 countries project in FH
Sam Gidding Unmet needs in children with FH
Jennifer Robinson ODYSSEY long term
Raul Santos ODYSSEY FH and patient unmet needs
Michel Farnier ODYSSEY FHI FHII
Alberto Zambon ODYSSEY trials at ESC Congress Hotline
Kausik Ray Residual cardiovascular risk – a role for PCSK9 inhibition
Dirk Blom FH issues in low to middle income regions
Raul Santos Improving the management of the FH patient
Dirk Blom The role of PCSK9 inhibitors in FH
Gerald Watts Implications from TESLA and early TAUSSIG studies with evolocumab
Frederick J. Raal Rationale for TESLA and results
Evan Stein Take home messages from ACC2014
Erik Stroes Do the PCSK9 inhibitors have pleiotropic effects?
Erik Stroes What are the current unmet needs?
Kausik Ray ACC/AHA guidelines: Where do the new treatments fit?
Evan Stein In your opinion, what are the optimum patient populations for PCSK9 monoclonal antibody therapy?